References
- Molitch ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999;28(1):143–69
- Asa SL. Pathology of pituitary tumors. Endocrinol Metab Clin North Am 1999;28(1):13–43
- Petraglia F, De Leo V, Nappi C, et al. Differences in the opioid control of luteinizing hormone secretion between pathological and iatrogenic hyperprolactinemic states. J Clin Endocrinol Metab 1987;64:508–11
- Khosla S, Melton g III. Secondary osteoporosis. In Riggs BL, Melton g III, eds. Osteoporosis — Etiology, Diagnosis and Management 2nd edn. Philadelphia, PA: Lippincott-Raven, 1995:185–7
- Klibanski A, Biller BM, Rosenthal DI, et al. Effects ofprolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988;67(1): 124–30
- Schlechte J, Walkner L, Kathol MA. Longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 1992;75(3):698–703
- Lindsay R. Estrogen defficiency. In Riggs BL, Melton g III, eds. Osteoporosis — Etiology, Diagnosis and Management, 2nd edn. USA: Lippincott-Raven, 1995:137–52
- Biller BM. Hyperprolactinemia. Int J Fertil Women's Med 1999;44:74–7
- Gluer C, Wu C, Hans D, et al. Ultrasound characterization of bone demineralization. Calqf Tissue Int 1998;62:133–9
- International Quantitative Ultrasound Consensus Group. Expert agreement on current status.J Bone Miner Res 1997;12:697–711
- Nystrome E, Leman J, Lundberg PA, et al. Bone mineral content in normally menstruating women with hyperprolactinemia. Horm Res 1988;29:214–17
- Koppelmann MCS, Kurtz DW, Morrish KA, et al. Vertebral body bone mineral content in hyper-prolactinemic women. J Clin Endocrinol Metab 1984;59:1050–3
- Stiegler C, Leb G, Kleinert R, etal. Plasma levels of parathyroid-related peptide are elevated in hyperprolactinemia and correlated to bone density status. J Bone Miner Res 1995;10(5):751–9
- To rring 0, Isberg B, Sjoberg HE, et al. Plasma calcitonin, IGF-I levels and bone mineral density in hyperprolactinemic women during bromocriptine treatment. Acta Endocrinol 1993; 128(5):423–7
- Schlechte JM, Sherman B, Martin R. Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 1983; 56:1120–4
- Fiore CE, Clementi G, Prato A, et al. Bone mineral content of the hyperprolactinemic rat femur by single photon absorbtiometry. Horm Metab Res 1988;20:40–3
- Clement-Lacroix P, Ormandy C, Lepescheux L, et al. Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knock-out mice. Obstet Gynecol Surv 1999;54: 383–4
- Park KH, Song CH. Bone mineral density in premenopausal anovulatory women. J Obstet Gynecol 1995;21:89–97